Q4 and full year 2025 saw double-digit sales and profit growth, margin expansion, and strong international performance, especially in Europe and APAC. 2026 guidance calls for continued revenue and earnings growth, with robust cash flow, increased dividends, and ongoing M&A activity.
Based on LeMaitre Vascular, Inc. [LMAT] Q4 2025 Audio Transcript — Feb. 25 2026
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
